To evaluate the Eﬃcacy of Teneligliptin as an add-on Therapy in type 2 Diabetes Mellitus (T2DM) Patients with Inadequate Glycemic Control with a Stable dose of Metformin 1 to 2g and Glimipride 1 to 6mg Per Day
Add-on Therapy in type 2 Diabetes Mellitus
Background: To evaluate the effectiveness of Teneligliptin as an add-on therapy in type 2 diabetes mellitus (T2DM) patients inadequately controlled with a stable dose of Metformin and Glimipride. Subjects and Methods: Pateints with type II DM on Metformin 1-2gm per day and Glimipride 1-4mg per day were prescribed with TENELIGLIPTIN 20mg tablet once daily. The patients Were followed up in OPD every month till 3 months. At the end of 3 months, Blood Pressure, Body weight CBC,KFT,LFT, Lipid Profile, Fasting Blood sugar, 2 hours Post parandial Blood sugar and HbA1c was assessed. The difference in all the mentioned parameters was used to determine the effectiveness of TENELIGLIPTIN. Result: There were more males as compared to females. Mean age among the study subjects was 59.08±12.17 years Family history of diabetes was revealed in 34.17% of the subjects.48.33% of the subjects had diabetes since 5-10 years. Hypertension and cardiovascular disease was revealed in 14.17% and 6.67% of the subjects respectively. After intervention, mean weight among study subjects reduced to 71.97 from 72.61. After intervention; HbA1c, FBS and PPBS reduced to 7.02±0.44, 131.70±6.17 and 204.95±9.39 Mean Triglyceride, HDL, LDL and VLDL among the study subjects was 151.76±6.19, 38.28±2.87, 108.11±6.43 and 39.32±3.12 among the study subjects. Conclusion: The present assessment shows patients with T2DM who were treated with teneligliptin had measurably large and clinical important reductions in HbA1c levels.
Copyright (c) 2021 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.